[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100303686":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":38,"centralContacts":42,"locations":48,"responsibleParty":67,"collaborators":26,"id":69,"slug":26,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":26,"eligibilityCriteria":74,"healthyVolunteers":75,"sex":76,"minAge":77,"maxAge":78,"enrollmentInfo":79,"targetDuration":26,"studyType":82,"phases":83,"briefSummary":85,"conditions":86,"keywords":90,"overallStatus":51,"whyStopped":26,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"NYU Langone Health","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Healthy Patients","ACTIVE_COMPARATOR","All healthy volunteers will complete the healthy volunteer form, MRI safety screening form, and the Montreal Cognitive Assessment (MOCA).",[13,14,15],"Device: Sham TMS3 stimulation","Device: rTMS of left or right angular gyrus (AG) or frontal cortex (FC)","Device: Anodal tDCS of left or right AG or FC",{"label":17,"type":10,"description":18,"interventionNames":19},"PMD\u002FPNES patients","PMD and PNES subjects will be referred by the treating",[13,14,15],[21,27,33],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Sham TMS3 stimulation","half of the subjects will receive sham stimulation first",[9,17],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":31},"rTMS of left or right angular gyrus (AG) or frontal cortex (FC)","Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.",[9,17],[32],"45 Minutes",{"type":22,"name":34,"description":29,"armGroupLabels":35,"otherNames":36},"Anodal tDCS of left or right AG or FC",[9,17],[37],"30 Minutes",[39],{"name":40,"affiliation":5,"role":41},"Biyu He, MD","PRINCIPAL_INVESTIGATOR",[43],{"name":44,"role":45,"phone":46,"phoneExt":26,"email":47},"Nalini Jeet","CONTACT","(212) 263-0228","Nalini.Jeet@nyulangone.org",[49],{"facility":50,"status":51,"city":52,"state":52,"zip":53,"country":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"New York University School of Medicine","RECRUITING","New York","10016","United States",{"type":56,"coordinates":57},"Point",[58,59],-74.00597,40.71427,{"lat":59,"lon":58},[62,66],{"name":63,"role":45,"phone":64,"phoneExt":26,"email":65},"Steven Stork","212-263-0001","steven.stork@nyumc.org",{"name":40,"role":41,"phone":26,"phoneExt":26,"email":26},{"type":68,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100303686",false,"NCT03233399","Modulating Movement Intention Via Cortical Stimulation","Modulating Movement Intention Via Cortical Stimulation in Healthy Subjects and Patients With Psychogenic Movement Disorders and Non-epileptic Seizures","Inclusion Criteria:\n\n(Healthy Controls)\n\n* Fluent in English\n\n(Patients with PMD or PNES):\n\n* Diagnosis of PMD\u002FPNES confirmed by a neurologist with expertise in movement disorders.\n* Per the treating neurologist, subject is unlikely to require treatment and\u002For dosage changes for 3-6 months following screening\n\nExclusion Criteria:\n\n* Any history of a significant neurological disorder, which may interfere with the interpretation of study data, as determined by the PI\n* Chronic or progressive medical condition\n* Any history of traumatic brain injury or significant head trauma\n* Currently meets criteria for substance abuse or dependence\n* History of any psychotic disorder or other psychiatric condition which may interfere with data interpretation\n* Pregnancy\n* Metal or devices in the head, including neurostimulators or metal foreign bodies\n* Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.\n* Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).\n* Taking tricyclic antidepressant or antiepileptic medications or CNS active drugs under \"strong potential hazard\" list in Rossi et al., 2009\n* Current diagnosis of any inflammatory or autoimmune disorder within last 6 months\n\nPMD and PNES Patients\n\n* Any history of traumatic brain injury or significant head trauma\n* Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonic seizures;\n* Neurological disorder other than PMD and PNES including stroke, fainting spells or syncope of unknown cause(s);\n* Major or unstable medical illness, especially any current diagnosis of inflammatory or autoimmune disorders within last 6 months\n* Metal or devices in the head, including neurostimulators or metal foreign bodies\n* Taking tricyclic antidepressant medications or CNS active drugs under \"strong potential hazard\" list in Rossi et al., 2009;\n* Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;\n* Recurrent visual hallucinations, within the past 6 months;\n* History of significant uncontrollable movements of the head;\n* Any clinically significant abnormality on vital signs",true,"ALL","18 Years","65 Years",{"count":80,"type":81},30,"ESTIMATED","INTERVENTIONAL",[84],"NA","The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.",[87,88,89],"Seizures","Seizure Disorder","Psychogenic Movement Disorder",[91,92,93],"Electroencephalography","Magnetoencephalography","Transcranial Magnetic Stimulation","2025-11-25",{"date":96,"type":97},"2025-11-28","ACTUAL",{"date":99,"type":97},"2017-07-20",{"date":101,"type":81},"2027-05",{"name":5,"class":6},1]